Jessica Cerka

@JessicaCerka

BioPharm Insight, part of The Mergermarket Group.

New York, NY
Joined May 2012
21 Photos and videos Photos and videos

Tweets

You blocked @JessicaCerka

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @JessicaCerka

  1. Retweeted
    Jun 7

    Celltrion to receive accounting investigation results early June, should resume its halted IPO process, reports

    1 retweet
  2. Retweeted
    Jun 6

    reports Bone Therapeutics receptive to CROs for cell therapy process development and Phase IIb trials

    1 retweet
  3. Retweeted
    Jun 6

    What do experts think of the potential Phase II success for Ardelyx’s RDX7675 in hyperkalaemia? & report

    1 retweet
  4. Retweeted
    Jun 5

    What do experts think of Kite Pharma’s CAR-T study cerebral edema death? reports

    1 retweet
  5. Retweeted
    Jun 2

    Eli Lilly’s Phase III trials of galcanezumab in cluster headache likely hitting enrolment roadblocks with indication severity, trial design

    1 retweet
  6. Retweeted
    May 26

    Will JCAR017 show positive Phase I overall response rate (ORR) data in diffuse large B-cell lymphoma (DLBCL)? reports

    1 retweet 1 like
  7. Retweeted
    May 25

    Amgen to present additional Phase III migraine data for erenumab from early time points at the American Headache Society in June

    1 retweet
  8. Retweeted
    May 18

    Merck's Keytruda becomes the 1st checkpoint inhibitor to get a full approval in advanced urothelial cancer

    1 retweet 1 like
  9. Retweeted
    May 23

    & report on Bayer’s Stivarga for second-line HCC, its use use in Nexavar-tolerant patients, side effects + efficacy

    3 retweets 1 like
  10. Retweeted
    May 24

    reports Arena’s ralinepag faces future Phase III development barriers with tough design benchmarks and a crowded PAH space

    2 retweets 2 likes
  11. Retweeted
    May 24

    + report on efficacy, safety, & trial design for Promethera's Phase IIa HepaStem for acute-on-chronic liver failure (ACLF)

    2 retweets
  12. Retweeted
    May 23

    . releases pre report;

    1 retweet
  13. Retweeted
    May 23

    Seattle Genetics Phase II NHL study of SGN-CD19A enrolls 50% of 150-patient target in 18 months, reported by

    3 retweets 3 likes
  14. Retweeted
    May 22

    Check out ’s report, your guide to the major catalysts and coverage

    1 retweet 1 like
  15. Retweeted
    May 19

    reports Sienna Biopharmaceuticals, a CA-based clinical stage dermatology and aesthetics co, is eying an IPO next after its series B

    1 retweet 1 like
  16. Retweeted
    May 18

    Asclegen (Wo En Sheng Wu), a Shanghai-based precision med service co, is raising CNY80m (US11.5m) for tech development & market expansions

    2 retweets 2 likes
  17. Retweeted
    May 19

    Will Eleison Pharma’s Holoxan (glufosfamide) reach OS in its Phase III second-line metastatic pancreatic cancer trial? reported by

    2 retweets 1 like
  18. Retweeted
    May 17

    Will Stemline's SL-401 face reimbursement hurdles? reports on potential uptake + payor pushback in BPDCN

    1 reply 1 retweet 1 like
  19. Retweeted
    May 16

    reports on Tesaro's Zejula (niraparib) pricing in ovarian cancer maintenance ! Contact us for access:

    1 retweet 3 likes
  20. Retweeted
    May 16

    SL-401 BPDCN approval won't be held back because of the capillary leak syndrome (CLS) but will have prominent risk labeling

    1 retweet 1 like

@JessicaCerka hasn't Tweeted yet.

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·